IMPACT OF INHERITED THROMBOPHILIA ON CANCER-ASSOCIATED THROMBOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Thrombosis and Haemostasis · 02.11.2026
DOI: 10.1055/a-2994-8843 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Thrombosis and Haemostasis, erschienen am 02.11.2026. Verfasst von Elena Campello und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Padua Department of Medicine, First Chair of Internal Medicine and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, Ve….
Abstract (Originalsprache)
Background:Cancer-associated thrombosis (CAT) is a cause of morbidity and mortality in patients with malignancy. The contribution of inherited thrombophilia remains incompletely defined.
Objectives
To evaluate the association between inherited thrombophilia and other genetic determinants and CAT risk in adults with malignancy.
Methods
We conducted a PRISMA 2020-compliant systematic review and meta-analysis of observational studies comparing genetic determinants in patients with cancer with and without VTE. Odds ratios (ORs) with 95% confidence intervals (CIs) were pooled using Mantel–Haenszel models. Risk of bias and certainty of evidence were assessed using the Newcastle–Ottawa Scale and GRADE, respectively.
Results
Twenty-one studies including 4,479 patients (1,115 with VTE) were included. Factor V Leiden (FVL) was associated with increased odds of CAT (OR 2.48, 95% CI 1.75–3.51; I²=32%), with consistent findings after exclusion of device- or catheter-related thrombosis. Heterozygous FVL was associated with CAT (OR 1.86, 95% CI 1.27–2.73), whereas the homozygous estimate was imprecise (OR 3.42, 95% CI 0.75–15.59). Prothrombin G20210A was associated with CAT (OR 2.67, 95% CI 1.56–4.58; I²=0%). Exploratory analyses yielded estimates for MTHFR (OR 1.40, 95% CI 1.02–1.93) and blood group O (OR 0.40, 95% CI 0.23–0.70); the latter was based on only two studies. Evidence for rarer determinants was sparse. Certainty was moderate for FVL and low or very low for other determinants.
Conclusions
FVL and prothrombin G20210A are associated with increased odds of CAT. Current evidence does not support universal genetic screening but warrants prospective evaluation of the incremental predictive value of genetic markers beyond established CAT risk models.
Autor:innen und Institutionen
- University of Padua Department of Medicine, First Chair of Internal Medicine and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, Veneto, Italy, Padua.
- University of Chieti, Internal Medicine, BO, Italy, Bologna.
- University of Padua Department of Medicine, Department of Medicine, Veneto, Italy, Padua.
- Università degli Studi di Padova, First Chair of Internal Medicine and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, Veneto, Italy, Padua.
- University of Padova, First Chair of Internal Medicine and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, Padua, Italy, Padua.
Zitieren
APA
Campello, E., Boccatonda, A., Furlan, G., Napolitano, A., Simion, C., & Simioni, P. (2026). IMPACT OF INHERITED THROMBOPHILIA ON CANCER-ASSOCIATED THROMBOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS. Thrombosis and Haemostasis. https://doi.org/10.1055/a-2994-8843
Vancouver
Campello E, Boccatonda A, Furlan G, Napolitano A, Simion C, Simioni P. IMPACT OF INHERITED THROMBOPHILIA ON CANCER-ASSOCIATED THROMBOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS. Thrombosis and Haemostasis. 2026. doi:10.1055/a-2994-8843
BibTeX
@article{Campello2026,
author = {Campello, Elena and Boccatonda, Andrea and Furlan, Giulia and Napolitano, Angela and Simion, Chiara and Simioni, Paolo},
title = {IMPACT OF INHERITED THROMBOPHILIA ON CANCER-ASSOCIATED THROMBOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS},
journal = {Thrombosis and Haemostasis},
year = {2026},
doi = {10.1055/a-2994-8843}
}
EUVIMED